Skip to content

Change in AR at other companies

Biogen logo
BiogenBIIB
-$25.68M+53.8%
Incyte logo
IncyteINCY
$27.03M+187%
AbbVie logo
AbbVieABBV
-$87M-106%
Nuvation Bio logo
Nuvation BioNUVB
$6.65M+154%
Opko Health logo
Opko HealthOPK
-$9.53M+58.5%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$4.36M-24.7%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.77B+95.0%

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Syndax Pharmaceuticals's change in AR?
Syndax Pharmaceuticals (SNDX) reported change in AR of -$120K in Q1 2026.
How has Syndax Pharmaceuticals's change in AR changed year-over-year?
Syndax Pharmaceuticals's change in AR decreased by 101.5% year-over-year, from $8.12M to -$120K.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.